Chemoradiation in Cancer Therapy

ISBN-13: 9781588290281 / Angielski / Twarda / 2002 / 420 str.

Hak Choy; Leo Broadley; Hak Choy

Opis

Internationally recognized experts in radiobiology describe herein the effects of tumour radiosensitivity with chemotherapeutic agents as well as combined modality therapy. The book details the current applications of combined modality therapy in a variety of tumour types. It demonstrates the integration of new specific molecular targeted agents into the mutimodality therapy, thus providing a new class of molecular targeted agents for radiation oncologists.

Recenzje

"Chemoradiaton in Cancer Therapy offers both clinical and basic oncologists not only a bold synthesis of the rapid and complex advances in new therapeutic modalities, but also highly practical guide to today's best strategies in cancer treatment." -Neoplasma

Spis treści

Part I. General/Background Chemoradiation: Biological Principles and Perspectives Hak Choy and Robert M. MacRae Fluoropyrimidines as Radiation Sensitizers Muhammad Wasif Saif and Robert B. Diasio Part II. Mechanisms of Interaction of Specific Chemotherapeutic Agents with Radiation The Role of Platinum Complexes in Combined Modality Therapy Beverly A. Teicher Taxanes in Combined Modality Therapy Robert M. MacRae and Hak Choy Camptothecin Radiation Sensitization Tyvin A. Rich The Role of Gemcitabine in Combined Modality Therapy Jerome Landry, William Blackstock, Robert M. MacRae, Gary Yang, and Hak Choy Part III. Clinical Applications Chemoradiation Strategies for Patients with Malignant Gliomas Heather A. Curry and Walter J. Curran, Jr. Combined Modality Strategies in the Treatment of Head and Neck Cancer Cathy Eng and Everett E. Vokes The Role of Combined Modality Therapy for Stage III Nonsmall-Cell Lung Cancer Roger W. Byhardt Combined Modality Treatment of Small-Cell Lung Cancer Julie R. Brahmer, Larry Kleinberg, and David S. Ettinger The Role of Chemoradiation in the Management of Esophageal Cancer Arlene Forastiere and Bapsi Chak Combined Modality Therapy in Locally Advanced Breast Cancer Silvia C. Formenti and Matthew Volm Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomas Alexandria Phan and Jaffer A. Ajani Chemoradiation in Therapy for Colon and Rectum Carcinoma Jason H. Lee and Christopher G. Willett Chemoradiotherapy in Muscle-Invasive Bladder Cancer Bruce J. Roth The Role of Combined Chemotherapy and Radiation Therapy in the Treatment of Gynecologic Malignancies Patricia J. Eifel Part IV. Specific Molecular Targeted Agents Overview of Specific Molecular Targeted Agents for Combined Modality Therapy Scott Saxman and Janet Dancey Receptor Tyrosine Kinases as Therapeutic Targets in Solid Tumors Stacy L. Moulder and Carlos L. Arteaga Adenoviral p53 Gene Therapy Strategies in Nonsmall-Cell Lung Cancer Stephen G. Swisher and Jack A. Roth Tumor Microvasculature as a Therapeutic Target During Radiotherapy Dennis E. Hallahan and Don Stacy Cancer Drug Discovery and Development: Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer Jeffrey S. Humphrey, Karen Price, Elora Gupta, Andrew Baxter, John Bird, Daryl Sonnichsen, and Joseph Naglich The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapy Hong Pyo, Raymond N. DuBois, and Hak Choy Index

Blurb

The combination of chemotherapeutic drugs and radiation to treat solid tumors has now become a common treatment option in many clinical settings. In Chemoradiation in Cancer Therapy, internationally recognized experts in cancer biology and clinical research review the present status of these multimodality approaches to the management of solid tumors and speculate on possible future strategies for their use. As part of their comprehensive survey, the authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers. They also show how radiation interacts with such chemotherapeutic agents as the platinum complexes, taxanes, and gemcitabine in the treatment of malignant gliomas, and head and neck cancer. Rounding out the presentation is a review of how to integrate new specific molecular-targeted agents into future multimodality therapy. Here the discussion centers on the antibody for the epidermal growth factor receptor (EGFR), antiangiogenesis agents, farnesyltransferase inhibitors (FTIs), gene therapies, and signaling pathway inhibitors in combination with radiotherapy, and with or without classical chemotherapeutic agents.
State-of-the-art and forward-looking, Chemoradiation in Cancer Therapy offers oncologists a thorough understanding of today's best current and future strategies available for the treatment of solid tumors by chemoradiation therapy.